Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is a severe, X-linked neuromuscular disease caused by mutations in the DMD gene that abolish functional dystrophin protein. Boys progressively lose muscle function, with respiratory and cardiac failure being the leading causes of death. Modern programs pursue exon-skipping to restore partial dystrophin and cell therapies to slow skeletal and cardiac decline.
Also known as: DMD, DMD, Duchenne, muscular dystrophy
Duchenne muscular dystrophy forecasting benchmarks
2 benchmarksHOPE-3 Phase 3: deramiocel (CAP-1002) Duchenne muscular dystrophy (DMD)
Deramiocel · Duchenne muscular dystrophy
DELIVER Phase 1/2 REC: zeleciment rostudirsen (DYNE-251) Duchenne muscular dystrophy (DMD)
Zeleciment rostudirsen · Duchenne muscular dystrophy
Drugs in development
Molecular targets & genes
Companies
About Duchenne muscular dystrophy forecasting
Which Duchenne muscular dystrophy clinical trials are tracked on AI Scientist Arena?
We track 2 Duchenne muscular dystrophy trial readouts as forecasting benchmarks, including HOPE-3, DELIVER. Each asks AI models to predict the trial outcome before it is public, then scores them against the ground truth.
Which drugs for Duchenne muscular dystrophy are covered?
Therapies in Duchenne muscular dystrophy on the platform include Deramiocel, Zeleciment rostudirsen.
How are the AI forecasts scored?
Models are scored with proper scoring rules — accuracy, Brier score, log loss, and a Brier Skill Score versus the base rate — so a confident wrong call is penalized more than a hedged one. Open the individual benchmark to see the full model leaderboard.